Rarestone Group

RareStone Group is committed to establishing Greater China's first integrated rare disease ecosystem, transforming the lives of patients and families through world-class therapeutics and comprehensive, sustainable support services. We have two subsidiaries under RareStone Group: Citrine Medicine is a specialty pharmaceutical company dedicated to delivering innovative, accessible treatments for rare diseases in Greater China, with a focus on neurology. WAKIX® is our core product, which has been approved by China NMPA in 2023 for narcolepsy, and it has been listed in the National Reimbursement Drug List in 2023. WAKIX® has obtained pediatric narcolepsy indication from China NMPA in May 2024. Zircon Health is a pioneering healthcare services platform building China's first rare disease ecosystem through- AI-powered, patient-centric disease management solutions - Digital health technologies and big data analytics - Comprehensive non-therapeutic support services - Innovative payment models to enhance treatment accessibility In July 2020, RareStone Group secured $80 million USD in Series A funding from leading investors including Eight Roads Ventures, F-Prime Capital, and Vivo Capital.